The FDA has approved cosibelimab (marketed under the brand name Unloxcyt), a new drug for adults with advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer.

BUFFALO, N.Y. — Four scholars, all considered trailblazers in the field of dental, oral and craniofacial research, have ...

Coherus BioSciences is expanding in immunotherapy while managing financial risks. Learn why CHRS stock may benefit from the ...